Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

SOMERSET, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at the end of January 2009 for discussion of the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. The pre-NDA meeting is an important step to complete prior to the planned submission of the final components of the ONCONASE rolling NDA for patients that have failed prior chemotherapy. Therefore, the final components of the rolling ONCONASE NDA will not be finalized until Alfacell receives guidance from the FDA at the pre-NDA meeting. Alfacell expects to provide an update on the planned completion of the rolling NDA within 48 hours of the conclusion of the pre-NDA meeting.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

Since receiving the results of this preliminary statistical analysis in late May 2008, the company engaged in an extensive and careful review of the data to submit to the FDA prior to the pre-NDA meeting. While preparations of materials for the pre-NDA meeting have taken more time than expected, by submitting the pre-NDA meeting request on October 3, 2008, Alfacell had anticipated that the pre-NDA meeting wo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... 28, 2014  MedSpring Urgent Care, an Austin ... S. Lamar Blvd., Austin, TX 78704 on ... on the southeast corner of Barton Springs Rd. and ... - 9 p.m. daily, including weekends and holidays. With ... Central Austin , Anderson Mill , Cedar ...
(Date:7/28/2014)... 28, 2014  TNI BioTech, Inc. (OTCQB: TNIB) ... on the development, marketing and distribution of opioid-related ... proxy materials with the Securities and Exchange Commission ... Shareholders to be held on Thursday, September 4, ... record date for determining those shareholders eligible to ...
Breaking Medicine Technology:MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ... loss from continuing operations of $513,000, or $0.16 per ... compared to income from continuing operations of $909,000, or ...
... OAKS, Calif., May 4, 2012  Amgen (NASDAQ: AMGN ... Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, ... vice president of Investor Relations at Amgen, will present. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
(Date:7/28/2014)... Fla. (PRWEB) July 28, 2014 Sarasota-based ... Florida’s Best Companies To Work For. Still headquartered in ... is the only Florida-domiciled company in the top ten ... Best Companies list appears in the August issue of ... medium and large employer categories. Ranked #7 for 2014, ...
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... HIV research findings made possible by a test developed ... Pharmaceutical Sciences (CU School of Pharmacy), AURORA, Colo (July 28, ... in the Colorado Antiviral Pharmacology Laboratory at the CU ... HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), ... , A study presented during the AIDS 2014 ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and ... raise investment capital through her crowd funding camping to ... United States. , According to a statement released by ... provide a great window of opportunity for investors like ... addition to this, Silverman looks at the 24/7 fitness ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than either ... expectation of hand-to-hand contact between patients and clinicians, ... issue of the American Journal of Infection ... for Professionals in Infection Control and Epidemiology (APIC). ... Biological, Environmental, and Rural Sciences at Aberystwyth University ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2
... Benefit from Fosamax, Boniva, Zometa does not apply to obese ... types of bone-building drugs used to prevent and treat osteoporosis ... research. , The study, which included 6,000 Wisconsin women aged ... such as Fosamax, Boniva and Zometa for more than two ...
... ... wireless fitness sector. , ... Cochrane, Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), ... ANT+ Alliance. A noted leader in the design and manufacturing of sport ...
... Twelve children ... attorneys like David Perecman understand frustration of the families. , ... New York, NY (PRWEB) March 5, 2010 -- The U.S. ... by Maclaren. However, as reported by the New York Post , this was ...
... ... partnership with leading SolidWorks and Agile PLM reseller GoEngineer to distribute DesignState Enterprise PDM ... to manage engineering data and collaborate across the enterprise with Oracle,s powerful Agile ... ...
... ... in the U.S., according to the Centers for Disease Control (CDC). , ... Charleston, SC (PRWEB) March 5, ... Infections (HAIs) and they have generated much attention over the last decade. Studies have ...
... ... Mikel J. Harry, the world renowned co-creator of Six Sigma and national ... achievement to the point of breakthrough – and beyond. In this ... can envision, plan and achieve extraordinary things. The Great Discovery® is a ...
Cached Medicine News:Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:Defective Child Product Recall Involves New York Personal Injury Attorneys 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 3Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma 2
Suture Cutter, Open Ended, Left Notch...
Threaded cannula with cannulated obturator for use with Acufex Suture Punch; sterile packs, box of 10....
...
...
Medicine Products: